Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.

Slides:



Advertisements
Similar presentations
Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Pomalidomide, Bortezomib.
Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Treatment of Immunoglobulin Light Chain Amyloidosis
Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Critiquing Cryos by Morie Gertz Blood Volume 111(11):
Therapy for Relapsed Multiple Myeloma
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Genetic sequence analysis of inherited bleeding diseases
A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization  Ivana N.M. Micallef,
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory.
Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.
Volume 2(Supplement 1):63-66
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
Renal Manifestations of Plasma Cell Disorders
by John J. Strouse, Megan E. Reller, David G
Sumit Madan, MD, Robert A. Kyle, MD, Philip R. Greipp, MD 
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
Activity of eltrombopag in severe aplastic anemia
Volume 73, Issue 11, Pages (June 2008)
Therapy for Relapsed Multiple Myeloma
Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and.
Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.
Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy
by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E
Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation  Shaji Kumar, Waleska S. Pérez, Mei-Jie.
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Volume 2(Supplement 1):1-3
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines  Stephen.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 
Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition  Terry M. Therneau, PhD,
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,
Plasma biomarker concentrations between study groups.
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,
Volume 2(Supplement 1):46-49
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Volume 2(Supplement 1):39-41
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.
by David Deambrosis, Su Han Lum, Ryan M
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis by Mohammed A. Aljama, M. Hasib Sidiqi,
by Robert A. Kyle, and S. Vincent Rajkumar
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.
Pure red cell aplasia by Robert T. Means Blood
Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.
Volume 2(Supplement 1):4-7
Cold agglutinin disease
Presentation transcript:

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Rahma Warsame, Taxiarchis V. Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, and Shaji K. Kumar BloodAdv Volume 2(22):3149-3154 November 27, 2018 © 2018 by The American Society of Hematology

Mohammed A. Aljama et al. Blood Adv 2018;2:3149-3154 © 2018 by The American Society of Hematology

Risk for progression to myeloma or related disorder in 306 patients with SMM, using a PCPI cutoff of 0.5. Risk for progression to myeloma or related disorder in 306 patients with SMM, using a PCPI cutoff of 0.5. Mohammed A. Aljama et al. Blood Adv 2018;2:3149-3154 © 2018 by The American Society of Hematology

Distribution of events in SMM patients at time of progression. Mohammed A. Aljama et al. Blood Adv 2018;2:3149-3154 © 2018 by The American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.